Compare Charles River Laboratories Intl. Inc (CRL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Novartis AG — how do they compare? Charles River Laboratories Intl. Inc trades at $300.53 (market cap $14.23B), while Novartis AG trades at $142.98 (market cap $268.57B). The key difference: Novartis AG is far larger — about 18.9× Charles River Laboratories Intl. Inc's market cap, and Novartis AG pays a 3.31% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Novartis AG for 82 Days on average.
| CRL | NVS | |
|---|---|---|
Market Cap | $14.23B | $268.57B |
Volume | 1,176,885 | 1,532,573 |
Sector | Health | Health |
52-Week High | $310.77 | $168.62 |
52-Week Low | $149.93 | $121.80 |
Typical Hold Time | 33 Days | 82 Days |
Enterprise Value | $17.06B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
